Pretargeted PET of Osteodestructive Lesions in Dogs
- 30 May 2022
- journal article
- research article
- Published by American Chemical Society (ACS) in Molecular Pharmaceutics
- Vol. 19 (9) , 3153-3162
Abstract
The last decade has played witness to the creation of a highly effective approach to in vivo pretargeting based on the inverse electron demand Diels-Alder (IEDDA) click ligation between tetrazine (Tz) and trans-cyclooctene (TCO). Despite the steady progression of this technology toward the clinic, concerns have persisted regarding whether this in vivo chemistry will work in humans given their larger size and blood volume. In this work, we describe the use of a 64Cu-labeled Tz radioligand ([64Cu]Cu-SarAr-Tz) and a TCO-bearing bisphosphonate (TCO-BP) for the pretargeted PET imaging of osteodestructive lesions in a large animal model: companion dogs. First, in a small animal pilot study, healthy mice were injected with TCO-BP followed after 1 or 6 h by [64Cu]Cu-SarAr-Tz. PET images were collected 1, 6, and 24 h after the administration of [64Cu]Cu-SarAr-Tz, revealing that this approach produced high activity concentrations in the bone (>20 and >15 %ID/g in the femur and humerus, respectively, at 24 h post-injection) as well as high target-to-background contrast. Subsequently, companion dogs (n = 5) presenting with osteodestructive lesions were administered TCO-BP (5 or 10 mg/kg) followed 1 h later by [64Cu]Cu-SarAr-Tz (2.2 – 7.3 mCi; 81.4 – 270.1 MBq). PET scans were collected for each dog 4 h after the administration of the radioligand, and SUV values for the osteodestructive lesions, healthy bone, and kidneys were determined. In these animals, pretargeted PET clearly delineated healthy bone and produced very high activity concentrations in osteodestructive lesions. Low levels of uptake were observed in all healthy organs except for the kidneys and bladder due to the renal excretion of excess radioligand. Ultimately, this work not only illustrates that pretargeted PET with TCO-BP and [64Cu]Cu-SarAr-Tz is an effective tool for the visualization of osteodestructive lesions but also demonstrates for the first time that in vivo pretargeting based on IEDDA click chemistry is feasible in large animals.Keywords
Funding Information
- National Cancer Institute (R01CA204167, R01CA240963, R01CA244327, R21EB030275, R35CA232130, U01CA221046)
This publication has 50 references indexed in Scilit:
- A Pretargeted PET Imaging Strategy Based on Bioorthogonal Diels–Alder Click ChemistryJournal of Nuclear Medicine, 2013
- Use of samarium Sm 153 lexidronam for the treatment of dogs with primary tumors of the skull: 20 cases (1986–2006)Journal of the American Veterinary Medical Association, 2012
- Bisphosphonates for postmenopausal osteoporosisBone, 2011
- Cancer RadioimmunotherapyImmunotherapy, 2011
- Bisphosphonates for the treatment of osteoporosis: insights for cliniciansTherapeutic Advances in Chronic Disease, 2010
- In Vivo Chemistry for Pretargeted Tumor Imaging in Live MiceAngewandte Chemie International Edition, 2010
- Tetrazine Ligation: Fast Bioconjugation Based on Inverse-Electron-Demand Diels−Alder ReactivityJournal of the American Chemical Society, 2008
- Bisphosphonates: Mechanism of Action and Role in Clinical PracticeMayo Clinic Proceedings, 2008
- Etidronate Therapy in the Treatment and Prevention of OsteoporosisJournal of Clinical Densitometry, 2000
- Bisphosphonates: A review of their pharmacokinetic propertiesBone, 1996